# Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

> **NCT04096417** · PHASE2 · UNKNOWN · sponsor: **Academic and Community Cancer Research United** · enrollment: 14 (actual)

## Conditions studied

- FGFR1 Gene Amplification
- FGFR1 Gene Mutation
- FGFR1 Gene Translocation
- FGFR2 Gene Amplification
- FGFR2 Gene Mutation
- FGFR2 Gene Translocation
- FGFR3 Gene Amplification
- FGFR3 Gene Mutation
- FGFR3 Gene Translocation
- Metastatic Colorectal Carcinoma
- Stage III Colorectal Cancer AJCC v8
- Stage IIIA Colorectal Cancer AJCC v8
- Stage IIIB Colorectal Cancer AJCC v8
- Stage IIIC Colorectal Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Stage IVA Colorectal Cancer AJCC v8
- Stage IVB Colorectal Cancer AJCC v8
- Stage IVC Colorectal Cancer AJCC v8
- Unresectable Colorectal Carcinoma

## Interventions

- **DRUG:** Pemigatinib
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT04096417
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-31
- **Primary completion:** 2022-05-13
- **Final completion:** 2025-12-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04096417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04096417, "Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04096417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*